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A B S T R A C T
Pyruvate kinase catalyses the last step in glycolysis and has been suggested to contribute to the regulation of
aerobic glycolysis in cancer cells. It can be inhibited by oxidation of cysteine residues in vitro and in vivo, which is
relevant to the more pro-oxidant state in cancer and proliferating tissues. These conditions also favour lipid
peroxidation and the formation of electrophilic fragmentation products, including short-chain aldehydes that
can covalently modify proteins. However, as yet few studies have investigated their interactions with pyruvate
kinase, so we investigated the eﬀects of three diﬀerent aldehydes, acrolein, malondialdehyde and 4-hydroxy-
2(E)-hexenal (HHE), on the structure and activity of the enzyme. Analysis by LC-MS/MS showed unique mod-
iﬁcation proﬁles for each aldehyde, but Cys152, Cys423 and Cys474 were the residues most susceptible to
electrophilic modiﬁcation. Analysis of enzymatic activity under these conditions showed that acrolein was the
strongest inhibitor, and at incubation times longer than 2 h, pathophysiological concentrations induced sig-
niﬁcant eﬀects. Treatment of MCF-7 cells with the aldehydes caused similar losses of pyruvate kinase activity to
those observed in vitro, and at lower concentrations than those required to cause cell death, with time and dose-
dependent eﬀects; acrolein adducts on Cys152 and Cys358 were detected. Cys358 and Cys474 are located at or
near the allosteric or active sites, and formation of adducts on these residues probably contributes to loss of
activity at low treatment concentrations. This study provides the ﬁrst detailed analysis of the structure-activity
relationship of C3 and C6 aldehydes with pyruvate kinase, and suggests that reactive short-chain aldehydes
generated in diseases with an oxidative aetiology or from environmental exposure such as smoking could be
involved in the metabolic alterations observed in cancer cells, through alteration of pyruvate kinase activity.
1. Introduction
The regulation of glycolysis is extremely important for the ﬂux of
metabolites required by cells under diﬀerent cellular conditions, and
highly proliferating cells, such as in tumors or bone marrow, show
upregulation of aerobic glycolysis, also known as the Warburg eﬀect
[1,2]. Tumour cells are known to have altered redox balance, with
higher cellular levels of reactive oxygen species, but also increased
antioxidant concentrations or activities [2,3], and this pro-oxidative
status is thought to be a requirement for their proliferative state,
through alterations in cell signaling pathways and metabolic repro-
gramming [3,4]. This may be achieved in part through redox modula-
tion of enzymatic activities, as various enzymes in glycolysis are known
to be sensitive to cellular redox balance, of which glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), pyruvate kinase M2 (PKM2), and
phosphofructokinase (PFK) are the most recognized [5]. GAPDH con-
tains a redox-sensitive cysteine in its catalytic site, oxidation of which
leads to direct inhibition of its activity [6-8]. It has also been reported
that under oxidative stress conditions, PFK can be regulated by oxida-
tive modiﬁcations of PFKFB3, which modulates the level of the allos-
teric activator fructose-2,6-bisphosphate. PFKFB3 can be S-glutathio-
nylated on Cys206, which is located near the substrate binding pocket
and causes decreased catalytic activity [9].
The last enzyme of glycolysis, pyruvate kinase, catalyses the con-
version of phosphoenolpyruvate and ADP to pyruvate and ATP. It is
considered to be a key player in the Warburg eﬀect as it has been ob-
served that tumours and other rapidly proliferating cells contain much
higher expression of the PKM2 isoform, which is subject to allosteric
regulation and has lower activity compared to the highly active non-
allosteric PKM1 isoform that is found in the majority of adult tissues
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[10,11]. PKM1 exists constitutively in the active, tetrameric form,
whereas PKM2 occurs in an equilibrium between monomer, dimer and
tetramer that can be inﬂuenced by the presence of a wide variety of
regulators [10]. For example, its activity is activated by the upstream
glycolytic metabolite fructose-1,6-bisphosphate (F-1,6-bP), which sta-
bilizes the tetramer, and in the absence of F-1,6-bP its activity drops to
4% [12-14]. Pyruvate kinase can also be inhibited by oxidants such as
H2O2, as it contains cysteine residues that are susceptible to oxidation,
for example Cys358, but the enzymatic activity can be recovered with a
reducing agent, demonstrating that inhibition is reversible [13,15,16].
Their oxidation can aﬀect substrate binding, binding of allosteric reg-
ulators, or multimerization [17]. Consequently, oxidation has been
suggested as a mechanism for inhibiting pyruvate kinase, for example in
lung cancer cells [15]. Although a strong dependence on glycolysis for
proliferating cells appears to be important, it has been proposed that
inhibition of pyruvate kinase during oxidative stress leads to rerouting
of glycolytic intermediates into the pentose phosphate pathway in order
to generate NADPH and maintain reduced glutathione levels, facil-
itating cell survival when partially reduced oxygen species (PROS) ac-
cumulate [18]. Studies in the eukaryotic model Saccharomyces cerevisiae
indicate that the build-up of PEP inhibits triose phosphate isomerase
and acts as a feedback loop to stimulate the pentose phosphate pathway
[19]. Such changes allow cancer cells to meet the increased biosyn-
thetic demands for antioxidants, lipids and nucleotides, promoting tu-
mour growth [11,20].
While it is clear that redox imbalance and increased production of
certain oxidants such as hydrogen peroxide or peroxynitrite can aﬀect
glycolytic enzymes directly, more reactive compounds such as hydroxyl
radicals can also damage other cellular components and cause lipid
peroxidation. The peroxidation of lipids containing polyunsaturated
fatty acids results in a wide range of reactive products, including short-
chain aldehydes that are reactive and can cause covalent modiﬁcations
of proteins [21,22]. This type of secondary damage is known as lipox-
idation and can occur via Schiﬀ's base formation with lysine residues or
formation of Michael adducts on histidine, cysteine or lysine residues
[23,24]. It has been shown to occur both in vitro and in vivo, and li-
poxidation products have been found in several inﬂammatory diseases,
including atherosclerosis and Alzheimer's disease [24]. Much attention
has focused on the lipid peroxidation product 4-hydroxynonenal (HNE),
which is often described as the most toxic aldehyde from this source
[25], owing to its high reactivity and potential for crosslinking, but a
variety of other products deserve consideration. The 6-carbon analogue
4-hydroxyhexenal (HHE) is one of the major lipid peroxidation pro-
ducts of ω-3 PUFAs; it has very comparable reactivity to HNE, and
therefore potential importance in disease [26]. The 3-carbon compound
malondialdehyde (MDA) is the most studied aldehyde [27] and in
parallel with HNE is commonly used as marker of oxidative stress [28],
although it should be noted that many of these studies used the TBARS
assay, which is not speciﬁc for malondialdehyde and is widely con-
sidered to be unreliable as an assay for endogenous oxidative stress
[29]. It is also bifunctional and has the potential to crosslink proteins
[30]. Acrolein is a 3-carbon alkenal more commonly associated with
tobacco smoke and processed foods [31], but it may also occur as a
breakdown product of lipid peroxidation [32]. It is highly reactive,
especially with thiol groups of proteins, and it has been associated
apoptosis and disruption of inﬂammation and antioxidant defence
regulation [33,34].
Interestingly, HNE has been suggested to have both pro-tumorigenic
and anti-cancer eﬀects. There is substantial evidence that many tumor
tissues contain increased levels of HNE adducts with proteins and DNA,
and HNE is thought to be both mutagenic and carcinogenic [35]. In
contrast, low levels of HNE have been reported to inhibit cell pro-
liferation and angiogenesis as well as inducing diﬀerentiation and
apoptosis in tumor cell lines [36]. Despite these links between lipox-
idation and cancer, as yet relatively little work has been done to study
the potential eﬀects of lipid peroxidation-derived aldehydes on
glycolytic enzymes involved in the Warburg eﬀect. GAPDH has been
investigated because the redox active catalytic cysteine appears to be
particularly susceptible to lipoxidation; it has been reported to be
modiﬁed by HNE in vitro [37] and by acrolein in mouse carcinoma cells
treated in culture [38]. Interestingly, such modiﬁcations were found to
cause aggregation, alter the subcellular localization of GAPDH and in-
duce some of its “moonlighting” functions [39,40]. In another study,
the sites and mechanism of GAPDH modiﬁcation by three diﬀerent α,β-
unsaturated carbonyl compounds were compared [41]. In contrast, li-
poxidation of pyruvate kinase had been largely unexplored until a re-
cent comparison of the eﬀects of HNE and its di-carbonyl analogue 4-
oxononenal (ONE) on PKM2, which demonstrated the potential of these
electrophiles to inactivate it [42]. In view of the gap in knowledge on
the interactions of short chain reactive alkanals and alkenals with
pyruvate kinase, we investigated the modiﬁcation of this protein by
acrolein, malondialdehyde and 4-hydroxyhexanal using LC-MS/MS to
map the sites of modiﬁcation following treatment in vitro. We then
determined the eﬀects of these treatments on PKM2 activity, both in
vitro and in the cultured cell line MCF-7, and assessed their impact on
cell viability with the aim of determining the potential of diﬀerent al-
dehydes reactivity to contribute to metabolic remodelling via PKM2.
2. Materials and methods
2.1. Chemicals
All reagents were purchased from Sigma-Aldrich Chemical Co.
(Dorset, UK) unless otherwise indicated. All solvents were of LC-MS
grade and ultrapure water (Type 1) was used for buﬀers and reactions.
Formic acid and dithiothreitol (DTT) were purchased from
ThermoFisher Scientiﬁc (Runcorn, UK).
2.2. Synthesis of 4-hydroxy-2(E)-hexenal
The 4-hydroxy-2(E)-hexenal (HHE) was obtained by cross-metath-
esis between acrolein and 1-penten-3-ol with Hoveyda-Grubbs catalyst
in good yield (68%), following the two published procedures [43,44].
1H NMR (300MHz, Acetone-d6) δ 9.57 (d, J=7.9 Hz, 1H), 6.96 (dd,
J=15.6, 4.4 Hz, 1H), 6.22 (ddd, J=15.6, 7.9, 1.7 Hz, 1H), 4.32 (ddt,
J=9.5, 6.7, 3.2 Hz, 1H), 4.22 (d, J=4.9 Hz, 1H), 1.83 – 1.42 (m, 2H),
0.94 (t, J=7.4 Hz, 3H); 13C NMR (75MHz, Acetone-d6) δ 193.1,
160.3, 130.3, 71.3, 29.2, 8.9.
2.3. Treatment of pyruvate kinase with aldehydes in vitro
Pyruvate kinase from rabbit muscle (EC2.7.1.40) was prepared at
2.5 mg/mL in phosphate buﬀer (7 mM sodium phosphate monobasic
and 10mM disodium phosphate dibasic, pH7.4) and treated with ac-
rolein (ACR), malondialdehyde (MDA) (prepared via acid hydrolysis of
1,1,3,3-tetramethoxypropane) or 4-hydroxy-2(E)-hexenal (HHE) at
2 μM, 10 μM, 20 μM, 38 μM, 100 μM, 200 μM, 380 μM, 500 μM, 760 μM,
1mM or 5mM and allowed to react for 10min, 30min, 1 h, 2 h or 4 h at
37°C. To stabilize adducts, sodium borohydride (NaBH4) was added to
the reaction to a ﬁnal concentration of 5mM and left for 30min at room
temperature. This step was omitted when the treated pyruvate kinase
was used in the enzymatic activity assay.
2.4. Cell culture and aldehyde treatment
MCF-7 cells were cultured in DMEM (Gibco, UK) supplemented with
10% fetal bovine serum (FBS), 100 U/ml penicillin and 100 μg/ml
streptomycin in a humidiﬁed incubator at 37°C and 5% CO2. For each
aldehyde treatment, cells were seeded into new ﬂasks at a cell density
of 106/mL and 10x stock solutions of ACR, MDA or HHE in phosphate
buﬀered containing 0.9% NaCl pH 7.4 were added to the culture media
to give ﬁnal concentrations of 2, 10, 20, 100 or 200 μM and incubated
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for 2, 4 or 24 h. Biological triplicates were performed.
2.5. XTT cell viability assay
MCF-7 cells were cultured in a 96-well plate at 105 cells per well.
The treatments with aldehydes were performed at the concentrations
and times described above. XTT [2,3-bis-(2-methoxy-4-nitro-5-sulfo-
phenyl)-2H-tetrazolium-5-carboxanilide] was dissolved in sterile
medium to a ﬁnal concentration of 1mg/mL. A 10mM solution PMS
(N-methyl dibenzopyrazine methyl sulfate) solution was prepared in
phosphate buﬀer saline (PBS). Immediately prior the start of the assay,
10 μL of PMS was added to 4mL of XTT solution; 25 μL of PMS/XTT
mixture was added to each well and the plate incubated in the dark for
2 h at 37°C before reading the absorbance at 450 nm. The assay was
performed with both technical and biological triplicates.
2.6. Cell harvesting, lysis and protein concentration assessment
Cells were harvested using pre-warmed trypsin-EDTA solution fol-
lowed by centrifugation at 150g for 5min at 4 °C and lysed in lysis
buﬀer (50mM Tris-HCl pH 7.5, 1 mM EDTA, 150mM NaCl, 1% Triton
X-100) supplemented immediately prior to usage with cOmplete™
EDTA-free Protease Inhibitor Cocktail (Sigma Aldrich, UK) according to
the manufacturer's instructions. After 15min incubation on ice, the
samples were centrifuged at 16,000 g for 2min and the supernatant
(cytosolic extract) was retained. The total protein concentration was
determined by the Bradford assay using Pierce™ Coomassie Plus Assay
Reagent (ThermoFisher Scientiﬁc, UK) in a 96-well plate: 5 μL of sample
or standard per well were mixed with 250 μL of Coomassie reagent and
after 10min the absorbance was read at 595 nm. Samples were ana-
lysed for enzymatic activity immediately.
2.7. Pyruvate kinase activity assays
Pyruvate kinase activity was measured by a coupled assay using
pyruvate-dependent conversion of NADH to NAD+ by lactate dehy-
drogenase as the reporter. For analysis of the eﬀects on pyruvate kinase
in vitro, 5 μL of the aldehyde-treated pyruvate kinase (equivalent to 1U)
were added to a cuvette containing 30 μL of 45mM adenosine 5′-di-
phosphate (ADP), 30 μL of 45mM phosphoenolpyruvate (PEP), 30 μL of
6.6 mM β-nicotinamide adenine dinucleotide reduced form (NADH)
and 5 μL of 200 U/mL lactate dehydrogenase (LDH) in 900 μL of 50mM
imidazole-HCl buﬀer pH 7.6, to give a ﬁnal volume of 1mL. The re-
action at 25 °C was monitored at 340 nm for 10min and the initial rate
of reaction in μmol NADH utilized/min was calculated. For analysis of
pyruvate kinase activity following cell treatments, the cytosolic extract
was substituted for the commercial pyruvate kinase preparation.
2.8. Protein in-solution digestion
To 100 μL of aldehyde-treated pyruvate kinase prepared as de-
scribed above, 100 μL of RapiGest SF (Waters, UK) were added and the
solution vortexed. DTT was then added to a ﬁnal concentration of 5mM
and the reaction incubated at 60 °C for 30min. Cysteine alkylation was
then performed by adding iodoacetamide to a ﬁnal concentration of
15mM and incubating in the dark for 30min at room temperature.
Trypsin (Trypsin Gold, Mass Spectrometry Grade, Promega,
Southampton, UK) was added to a ﬁnal concentration of 7 μg/mL and
the samples were incubated overnight at 37 °C. To prepare samples for
LC/MS, triﬂuoroacetic acid (TFA) was added to a ﬁnal concentration of
0.5% and the reaction incubated at 37 °C for 45min, during which time
a precipitate formed. Acid-treated samples were centrifuged at 16000 g
for 10min then the supernatant carefully transferred to another tube
and dried in a centrifugal evaporator and stored dry at -20 °C. Samples
were resuspended in H2O/acetonitrile (98%/2%), 0.1% formic acid
prior to MS analysis.
2.9. Liquid chromatography-tandem mass spectrometry (LC-MS/MS)
analysis
Peptides were separated and analysed using an Ultimate 3000
system (Thermo Scientiﬁc, Hemel Hemstead, UK) coupled to a 5600
TripleTOF (ABSciex, Warrington, UK). The analysis was performed as
previously described [45]. Brieﬂy, the peptide solution was loaded onto
a C18 trap column (C18 PepMapTM, 5 μm, 0.5 x 5mm, Thermo Sci-
entiﬁc, Hemel Hemstead, UK) before separation on a nano-HPLC
column (C18 PepMapTM, 5 μm, 0.075 x 150mm, Thermo Scientiﬁc,
Hemel Hemstead, UK) at 300 nL/min using a gradient elution running
from 2% to 45% aqueous acetonitrile, 0.1% formic acid over 45min.
Ionization of the peptides was achieved with the spray voltage set at
2.4 kV, a source temperature of 150oC, declustering potential of 100 V
and a curtain gas setting of 25. Survey scans were collected in positive
mode from 350 to 2000 Da using high-sensitivity TOF-MS mode. In-
formation-dependent acquisition (IDA) was used to collect MS/MS data
using the following criteria: the 10 most intense ions with +2 to +5
charge states and a minimum intensity of 200 cps were chosen for
analysis, using dynamic exclusion for 12 s and standard rolling collision
energy settings.
2.10. Database searches
The Mascot® probability based search engine (Matrix Science,
London, version 2.4.0) was used to interrogate the SwissProt 2019_03
primary database. LC-MS .wiﬀ ﬁles of each sample were searched for
protein identiﬁcation and oxidative post-translational modiﬁcations
(oxPTMs). For protein identiﬁcation, variable modiﬁcations of me-
thionine oxidation and carbamidomethyl cysteine were used. For the
analysis of the lipoxidation products, the initial searches additionally
used a variable modiﬁcation list including reduced and unreduced ACR
(mass changes of 56.06 Da, 58.08 Da, 40.06 Da, 94.11 Da, 56.06 Da,
76.09 Da), MDA (mass changes of 54.05 Da, 56.06 Da, 134.13 Da,
36.03 Da and 26.04 Da) or HHE (mass changes of 114.14 Da, 93.13 Da,
78.11 Da) adducts at cysteine, lysine and histidine residues. Other
parameters for the searches were as follows: Enzyme: Trypsin; Peptide
tolerance:± 0.6 Da; MS/MS tolerance:± 0.6 Da; Peptide charge state:
+2, +3; Max Missed cleavages: 1; #13C: 0; Quantitation: None;
Instrument: ESI-QUAD-TOF; Data format: Mascot Generic;
Experimental mass values: Monoisotopic; Taxonomy: Chordata. All data
identifying modiﬁcations were manually validated before inclusion.
2.11. Statistical analysis
Data were analysed with Graph Pad Prism using one-way ANOVA
for single time point (Fig. 2 and Suppl. Figure 2) and using two-way
ANOVA for multiple time point (Fig. 3 and Fig. 4), both with Dunnett's
multiple comparisons test, comparing the values of each treated sample
to the mean of the untreated control, normalized to 100%. Data are
shown as averages ± SEM.
3. Results
3.1. Identiﬁcation and mapping of lipoxidation on pyruvate kinase
following 10 min treatments
The modiﬁcation of pyruvate kinase by acrolein, MDA and HHE was
investigated using LC-MS/MS to map the sites of modiﬁcation following
treatment in vitro at 37 °C for 10min. Initially the MASCOT® software
was used to identify modiﬁed peptides, and then each potential mod-
iﬁcation was conﬁrmed by de novo sequencing of the MS/MS spectrum
including detection of diagnostic ions as reported previously [46]; ex-
amples of modiﬁcation by each aldehyde are shown in Suppl. Figures 1
and 2. This approach allowed the identiﬁcation of 11 peptides modiﬁed
by acrolein, 10 peptides modiﬁed by HHE and 9 peptides modiﬁed by
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MDA based on peptide molecular weight, mass/charge ratio and charge
of the peptide ion, MS/MS ion score and LC retention time (Table 1).
Acrolein adducts were either Schiﬀ's bases (+40 Da), Michael adducts
(+58 Da) or FDP adducts (+96 Da), while for HHE Schiﬀ's bases oc-
curred at +96 Da and Michael adducts at +114 Da; only Schiﬀ's bases
(+54 Da) were formed with malondialdehyde. The majority of the
identiﬁed adducts occurred on lysine and cysteine residues, although
some histidine adducts were identiﬁed. The position of the modiﬁed
residues in the enzyme structure is shown in Fig. 1. It can be seen that
the susceptibility of residues identiﬁed as modiﬁed diﬀered sub-
stantially between the aldehydes: the proﬁles of modiﬁcation were most
similar between acrolein and HHE, as would be expected considering
that they are both α,β-unsaturated aldehydes, but even so there were
Fig. 1. Mapping of lipoxidation adducts to the crystal structure of pyr-
uvate kinase. Backbone structure with modiﬁed residues indicated in space-ﬁll
form, showing the location of adducts of acrolein (A), HHE (B) and MDA (C).
The modiﬁed residues are color-coded with orange indicating those found only
at 380 μM, green for those found additionally at 760 μM and blue for ones found
additionally at 5mM. (For interpretation of the references to color in this ﬁgure
legend, the reader is referred to the Web version of this article.)
Fig. 2. Inverse relationship of the dose-dependent eﬀect of aldehydes on
the activity of pyruvate kinase in vitro and the percentage of modiﬁed
pyruvate kinase peptides identiﬁed. Pyruvate kinase (PYK) was treated with
38 μM, 380 μM, 760 μM and 5 mM ﬁnal concentrations of acrolein, 4-hydroxy-
hexenal or malondialdehyde for 10 min before the assessment of its activity by
spectrophotometric assay of NADH oxidation at 340 nm (n=4; Mean ± SEM;
*p < 0.1 **p < 0.01 ***p < 0.001 ****p < 0.0001). Peptide modiﬁcation
was determined from the total number of modiﬁed peptides as a % of the total
modiﬁable peptides in the sequence.
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clear diﬀerences (e.g. HHE formed adducts on C152, K188, K247, H379
that were not detected with acrolein, whereas acrolein modiﬁed K66,
K166, K207 and H464). MDA gave a rather diﬀerent proﬁle, as only
lysine adducts were formed and modiﬁcations on K115, K224 and K270
were unique to this aldehyde. Only K393 and K475 were consistently
identiﬁed by MASCOT as modiﬁed by all aldehydes. To investigate
further the factors aﬀecting the sites of modiﬁcation, the modiﬁcations
were also mapped onto space-ﬁlling models that were colour-coded to
indicate the hydrophobicity of the location (Suppl. Figure 3), and short
videos were prepared to enable clearer 3 dimensional visualization
(Suppl. Material Videos 1-3). Overall, it can be seen that there was no
clear correlation between the hydrophobicity and site of modiﬁcation,
and a number of modiﬁcations observed at lower treatment con-
centrations occurred at relatively polar sites, either on the surface of the
enzyme or in clefts. The most notable observation was that acrolein was
Fig. 3. Eﬀect of longer treatments with acrolein, 4-hydroxy-hexenal and
malondialdehyde on the activity of pyruvate kinase in vitro. Pyruvate ki-
nase was treated with 2 μM, 10 μM, 20 μM and 100 μM of each aldehyde for
30 min, 1 h, 2 h or 4 h before the assessment of its activity (n=3;
Mean ± SEM; *p < 0.1 **p < 0.01, ***p < 0.001 and ****p < 0.0001).
Fig. 4. Mapping of lipoxidation adducts formed at low concentrations for
4 h treatments. Backbone structure with modiﬁed residues indicated in space-
ﬁll form, showing the location of adducts of acrolein at 2 h (A); acrolein at
4 h (B) and HHE at both time points (C). The modiﬁed residues are color-coded
with yellow indicating those found only at 10 μM, orange for those found ad-
ditionally at 20 μM, green for those found additionally at 100 μM and blue for
ones found additionally at 200 μM. (For interpretation of the references to color
in this ﬁgure legend, the reader is referred to the Web version of this article.)
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able to penetrate more readily into narrow pockets in the enzyme,
compared to HHE.
3.2. Inhibition of pyruvate kinase activity following treatment in vitro
The eﬀect of the same treatment time and concentrations on pyr-
uvate kinase activity were determined in vitro by a coupled spectro-
photometric assay. All acrolein and HHE treatments had a signiﬁcant
dose-dependent eﬀect on the enzymatic activity, while MDA treatments
at lower concentration had no eﬀect and a decrease in activity was only
observed at the highest concentration of 5mM (Fig. 2). The number of
modiﬁed peptides detected as a percentage of the total number of
modiﬁable tryptic peptides in the protein are shown in Fig. 2 and a
clear inverse relationship between activity and modiﬁcation can be
seen. HHE gave the highest maximum number of modiﬁed peptides,
followed by acrolein, and MDA was the lowest, reﬂecting the fact that
only lysine residues can be modiﬁed by this aldehyde. However, at
380 μM treatment, MDA actually gave a higher percentage of modiﬁed
peptides than the other two aldehydes. Subsequently, the eﬀects of a
wider range of treatment concentrations that included physiological
(2 μM) to pathophysiological (20-100 μM) concentrations on pyruvate
kinase activity were tested (Suppl. Figure 4). It can be seen that acrolein
caused a dose-dependent decrease in the activity of pyruvate kinase,
with 70% activity at 100 μM and 200 μM, 40% at 500 μM and 10% at
1mM treatment, corresponding to substantially more inhibition than
either of the other aldehydes.
3.3. Eﬀect of longer treatment times on activity and lipoxidation of pyruvate
kinase
It was noted that the treatment concentrations required to cause
signiﬁcant inhibition were extremely high, and it was hypothesized that
this might relate to the very short incubation times tested initially,
despite the fact that the reaction of acrolein with protein was expected
to be rapid. Therefore, further experiments were carried out with longer
incubations of 30min to 4 h with the lower range of concentrations for
each aldehyde (Fig. 3). Both acrolein and HHE showed a general time-
dependent trend, with longer incubations showing more extensive in-
hibition of activity. After 1 h reaction with acrolein, signiﬁcant eﬀects
on the activity were observed above 10 μM, with only 40% activity
remaining in the 100 μM treatment. A 2 h incubation caused a decrease
in activity to approximately 20% at treatment concentrations of 100μM
or greater, and further inhibition was observed after 4 h reaction with
40% activity remaining at 10 μM, a known pathophysiological
Table 1
Pyruvate kinase residues modiﬁed after 10min treatment at high aldehyde concentrations in vitro
Modiﬁed
Residues








m/z (charge) Ion score Rt (min) Aldehyde treatment
38 μM 380 μM 760 μM 5mM
Acrolein
Cys49 44NTGIIC+56TIGPASR56 1357.70 1357.83 679.9 (2+) 52 27.76 - - - ✓
Cys49 44NTGIIC+58TIGPASR56 1359.72 1359.84 680.9 (2+) 54 27.69 - ✓ ✓ ✓
Lys66 63EMIK+58SGMNVAR73 1292.66 1292.81 431.9 (3+) 16 21.87 - - ✓ ✓
Lys166 163NIC*K+58VVDVGSK173 1275.68 1275.81 638.9 (2+) 13 21.94 - - ✓ ✓
Lys207 207K+40GVNLPGAAVDLPAVSEK224 1804.01 1804.19 602.4 (3+) 62 31.00 - - - ✓
Cys326 320AGKPVIC+58ATQMLESMIK336 1876.98 1876.17 626.7 (3+) 19 52.72 - - - ✓
Cys358 343AEGSDVANAVLDGADC+58IMLSGETAK367 2494.16 2494.37 832.5 (3+) 37 49.48 ✓ - - -
Lys367 343AEGSDVANAVLDGADC*IMLSGETAK+58GDYPLEAVR376 3551.67 3551.99 889.0 (4+) 26 47.52 - ✓ - -
Lys393 393K+58LFELAR400 1062.61 1062.72 532.4 (2+) 27 29.34 - - ✓ ✓
Lys393 393K+40LFELAR400 1060.59 1060.63 531.3 (2+) 9 21.87 - - ✓ ✓
Cys423 423C+58LAAALIVLTESGR436 1473.82 1473.96 737.9 (2+) 89 51.53 - - - ✓
His464 462QAH+40LYR467 826.44 826.51 414.3 (2+) 21 21.03 ✓ - - -
Cys474 468GIFPVVC+58K475 975.55 975.63 460.8 (2+) 31 30.97 ✓ ✓ ✓ ✓
Lys475 468GIFPVVC*K+58DPVQEAWAEDVDLR489 2599.30 2599.51 867.5 (3+) 57 53.72 - - ✓ ✓
4-Hydroxy-hexenal
Cys152 152C+96DENILWLDYK162 1506.71 1506.86 754.44 (2+) 24 39.35 - ✓ ✓ ✓
Cys152 152C+114DENILWLDYK162 1524.72 1524.72 763.43 (2+) 72 33.52 ✓ ✓ ✓ ✓
Lys188 187QK+114GPDFLVTEVENGGFLGSK206 2235.14 2235.34 746.12 (3+) 17 35.84 - - - ✓
Lys247 247K+96AADVHEVR255 1119.60 1119.73 374.25 (3+) 27 18.23 - - - ✓
Cys326 320AGKPVIC+96ATQMLESMIKKPRPTR342 2650.45 2650.72 531.15 (5+) 14 38.00 - - - ✓
Cys326 320AGKPVIC+114ATQMLESMIKKPRPTR342 2668.46 2668.72 445.79 (6+) 13 29.35 - - - ✓
Cys358 343AEGSDVANAVLDGADC+114IMLSGETAK367 2550.18 2550.42 851.15 (3+) 36 36.37 - ✓ ✓ ✓
His379 377MQH+114LIAR383 981.54 981.64 491.83 (2+) 13 19.81 - - ✓ ✓
His391 384EAEAAMFH+114R392 1174.54 1174.67 392.56 (3+) 10 21.82 - - - ✓
Lys393 393K+114LFEELAR400 1118.63 1118.72 560.37 (2+) 26 29.38 - ✓ ✓ ✓
Cys423 423C+96LAAALIVLTESGR436 1529.85 1529.98 765.99 (2+) 76 40.94 ✓ ✓ ✓ ✓
Cys474 468GIFPVVC+114K475 975.55 975.62 488.82 (2+) 26 28.22 - - ✓ ✓
Lys475 468GIFPVVCK+114DPVQEAWAEDVDLR489 2599.29 2599.49 867.50 (3+) 85 33.83 - - - ✓
Malondialdehyde
Lys115 93TATESFASDPILYRPVAVALDTK+54GPEIR120 3070.59 3070.81 768.71 (4+) 42 34.07 - ✓ - ✓
Lys135 126GSGTAEVELK+54K136 1171.61 1171.52 391.51 (3+) 52 18.74 - ✓ ✓ -
Lys188 187QK+54GPDFLVTEVENGGFLGSK206 2175.08 2175.21 726.08 (3+) 94 34.69 ✓ ✓ ✓ ✓
Lys207 207K+54GVNLPGAAVDLPAVSEK224 1817.99 1818.03 607.02 (3+) 70 28.67 ✓ ✓ ✓ ✓
Lys224 208GVNLPGAAVDLPAVSEK+54DIQDLK230 2402.27 2402.45 801.82 (3+) 87 33.97 - ✓ ✓ ✓
Lys270 267IISK+54IENHEGVR278 1447.78 1447.74 483.59 (3+) 82 23.05 - - - ✓
Lys305 295GDLGIEIPAEK+54VFLAQK311 1881.03 1881.08 628.03 (3+) 48 34.80 - - - ✓
Lys393 393K+54LFEELAR400 1058.58 1058.57 530.29 (2+) 37 27.85 ✓ ✓ ✓ ✓
Lys475 468GIFPVVC*K+54DPVQEAWAEDVDLR489 2596.26 2596.49 866.50 (3+) 72 36.79 ✓ ✓ ✓ ✓
a (subscript) – amino acid position in the mature protein.
b (superscript) - mass diﬀerence corresponding to the modiﬁcation.
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concentration [47,48] and 20% at 100 μM. In the case of HHE, at a
treatment concentration of 100 μM the eﬀect on the activity of pyruvate
kinase was time-dependent, with 70% remaining after 30min, 55%
after 1 h, 40% after 2 h and 30% after 4 h. Comparing the two alde-
hydes, acrolein appeared to cause more inhibition. Unlike the α,β-un-
saturated aldehydes, MDA did not show a clear dose or time-dependent
eﬀect on the activity of pyruvate kinase, although signiﬁcant inhibition
was observed at all concentrations following a 2 h treatment. LC-MS/
MS analysis of the modiﬁed pyruvate kinase after 4 h allowed the
identiﬁcation of 10 peptides modiﬁed by acrolein and 4 peptides
modiﬁed by HHE (Table 2). Mostly the same adducts were observed
after 2 h (Suppl. Table 1), except that Lys166, Lys207 and His391 were
only found at 4 h, and Lys188 and His464 were only found at 2 h. All
the amino acid residues found to be modiﬁed with the longer and lower
treatments were ones that were modiﬁed after short high concentration
treatments with acrolein and HHE, but no MDA adducts could be de-
tected. As at the shorter treatment times, there was an inverse re-
lationship between enzyme activity and % of peptides modiﬁed, al-
though the total level of modiﬁcation was much lower for these
treatment concentrations (Suppl. Fig. 5). The sites of modiﬁcations
were mapped to the 3D crystal structure, and are shown in Fig. 4; it can
be seen that cysteine residues were the most sensitive to adduct for-
mation with both acrolein and HHE. Suppl. Fig. 6 and Suppl. Material
Videos 4-6 show the hydrophobicity of these sites, and support the lack
of obvious correlation noted above.
3.4. Comparison of aldehyde eﬀects on MCF-7 cell pyruvate kinase activity
and cell viability
To investigate the ability of the aldehydes to cause inhibition of
pyruvate kinase in a cellular environment, MCF-7 cells were treated in
culture with aldehydes and their impact on extractable pyruvate kinase
activity and cell viability was tested. Cells were treated with the same
acrolein, MDA and HHE concentrations as above for 2 h or 24 h (Fig. 5).
Two hour treatments at 10 μM acrolein inhibited the activity of pyr-
uvate kinase to 20% of control (A), while higher concentration treat-
ments had an even more severe eﬀect on the activity of the enzyme.
Interestingly, cellular pyruvate kinase activity seemed to be less sensi-
tive to 24-h acrolein treatment with 2-10 μM acrolein, although at
higher concentrations the eﬀect was very similar to 2 h. In contrast, the
cell viability showed a slightly diﬀerent response to treatments at the
two time points. Neither treatment time with acrolein caused sig-
niﬁcant loss of cell viability until concentrations of 100 μM, but the
higher concentrations were more toxic at 24 h (Fig. 5B). HHE caused a
similar, though more gradual, decrease in the enzymatic activity. The
2 h treatment at 10 μM inhibited the activity of pyruvate kinase to 60%
of control (Fig. 5C) and higher concentration treatments caused an even
more severe eﬀect. As with acrolein, pyruvate kinase activity seemed to
be less sensitive to 24 h HHE treatment at all concentrations. Interest-
ingly, these treatments only caused a maximum of 20% of loss in cell
viability (Fig. 5D). A similar, though smaller, eﬀect on cellular pyruvate
kinase activity was observed for MDA treatments (Fig. 5E); there was a
concentration-dependent loss of pyruvate kinase activity that appeared
greater for the 2 h treatment compared to 24 h, but in contrast to ac-
rolein, MDA caused no signiﬁcant loss of viability at any concentration
or either time point (Fig. 5F). Extracts of cells treated with 10 and
200 μM acrolein were also subjected to in-gel digestion and analysed by
LC-MS/MS to search for modiﬁcations of cellular pyruvate kinase. Al-
though the sequence coverage was low, modiﬁcations on Cys152 and
Cys358 were detected (Suppl. Table 2 and Suppl. Fig. 7), in agreement
with the data from treatments of pyruvate kinase in vitro, which sug-
gested that these residues are highly susceptible to adduct formation.
4. Discussion
Pyruvate kinase is an important regulatory enzyme in glycolysis,
and changes in its expression level, isoform and activity have been
linked to the switch to aerobic glycolysis in cancer and proliferating
cells [49]. Cancer cells also have altered redox status [4] leading to
increased lipid peroxidation and formation of electrophilic short chain
carbonyl species, but previously there have been few studies of their
eﬀects on pyruvate kinase. To address this question, we measured the
inhibition of pyruvate kinase activity caused by incubation with acro-
lein, HHE and MDA in vitro, and analysed the formation of protein-
Table 2
Pyruvate kinase residues modiﬁed after 4 h treatment with low concentrations of aldehydes.
Modiﬁed
Residues








m/z (charge) Ion score Rt (min) Aldehyde treatment (4 h)
2 μM 10 μM 20 μM 100 μM 200 μM
Acrolein
Cys49 44NTGIIC+58TIGPASR56 1359.72 1359.61 680.81 (2+) 80 15.97 - ✓ ✓ ✓ ✓
Cys152 152C+58DENILWLDYK162 1468.69 1468.58 735.29 (2+) 91 19.57 ✓ ✓ ✓ ✓ ✓
Lys166 163NIC*K+58VVDVGSK173 1275.68 1275.57 426.19 (3+) 26 11.56 - - - - ✓
Lys207 207K+58GVNLPGAAVDLPAVSEK224 1822.02 1821.83 608.28 (3+) 16 16.21 - - - - ✓
Lys207 207K+96GVNLPGAAVDLPAVSEK224 1860.04 1859.89 620.97 (3+) 44 16.47 - - - - ✓
Cys358 343AEGSDVANAVLDGADC+58IMLSGETAK367 2494.16 2493.97 832.33 (3+) 118 21.22 - - - ✓ ✓
His391 384EAEAAMFH+58R392 1118.52 1118.41 373.81 (3+) 46 11.64 - - - - ✓
Lys393 393K+58LFELAR400 1062.61 1062.51 355.18 (3+) 37 14.66 - - - - ✓
Lys393 393K+96LFELAR400 1100.62 1100.52 367.84 (3+) 39 14.83 - - - - ✓
Cys423 423C+58LAAALIVLTESGR436 1473.82 1473.71 737.86 (2+) 108 20.72 - ✓ ✓ ✓ ✓
Cys474 468GIFPVVC+58K475 919.52 919.44 460.72 (2+) 47 17.13 - ✓ ✓ ✓ ✓
Lys475 468GIFPVVC*K+58DPVQEAWAEDVDLR489 2543.27 2543.10 848.71 (3+) 103 19.99 - - - ✓ ✓
4-Hydroxy-2-hexenal
Cys152 152C+96DENILWLDYK162 1506.71 1506.61 754.31 (2+) 18 22.46 - - - - ✓
Cys152 152C+114DENILWLDYK162 1524.72 1524.59 763.30 (2+) 46 20.12 ✓ ✓ ✓ ✓ ✓
Cys423 423C+114LAAALIVLTESGR436 1529.85 1529.72 765.87 (2+) 77 22.37 ✓ ✓ ✓ ✓ ✓
Cys474 468GIFPVVC+114K475 975.55 975.44 488.73 (2+) 26 16.76 - - ✓ ✓ ✓
Lys475 468GIFPVVCK+114DPVQEAWAEDVDLR489 2599.29 2599.11 867.38 (3+) 91 18.97 - - ✓ ✓ ✓
Malondialdehyde
No modiﬁcations detected
a (subscript) – amino acid position in the mature protein.
b (superscript) - mass diﬀerence corresponding to the modiﬁcation.
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aldehyde adducts. There was clearly an inverse relationship between
the extent of adduct formation and the activity of the enzyme for all
three aldehydes. The data showed that acrolein caused the greatest
inhibition of pyruvate kinase, while HHE had an intermediate eﬀect
and MDA had no signiﬁcant eﬀect until much higher concentrations.
The lack of inhibition by MDA probably relates to its diﬀerent chem-
istry, speciﬁcally that it is only able to react with lysines to form Schiﬀ's
base adducts, although like the other aldehydes it can cause cross-
linking. The mass spectrometry data strongly suggested diﬀerent pro-
ﬁles of susceptibility of pyruvate kinase residues to the aldehydes. It
was also observed that the extent of inhibition was dependent on the
length of incubation as well as the treatment concentration, with longer
treatments leading to loss of activity at much lower and physiologically
relevant concentrations. This demonstrates that the reactions are rela-
tively slow to reach equilibrium and moreover suggests that reversi-
bility of adduct formation is not a signiﬁcant factor. In cells treated with
aldehydes, pyruvate kinase activity was lost at slightly lower con-
centrations than for the treatment in vitro, and did not correlate with
loss of cell viability until the highest treatment concentrations, in-
dicating that the enzymatic eﬀect was not simply due to general cell
dysfunction. Interestingly, it has been reported previously that tumour
cells can survive and proliferate with very low pyruvate kinase activity
[50].
The variation in residue susceptibility to the three aldehydes was
notable. Even with acrolein and HHE, which are both α,β-alkenals that
can form Michael adducts with cysteine and histidine, although there
were six common modiﬁed residues (Cys326, Cys358, Lys393, Cys423,
Cys474, Lys475) following short treatments at higher concentrations,
there were also several diﬀerences. This may be a result of the smaller
size of acrolein and a corresponding ability to access more buried re-
sidues, such as Cys49, Lys207 and His464. This was apparent from the
video clips of the space ﬁlling models. Some additional residues mod-
iﬁed by HHE seemed to be surface accessible, including Lys188 and
Lys247, so it is unclear why these were not adducted by acrolein;
mapping of the surface hydrophobicity did not suggest that it correlated
strongly to this factor. The only overlap between MDA modiﬁcations
and both other aldehydes was in adducts on Lys393 and Lys475, while
at lower concentrations no modiﬁcations by MDA were detected. It is
important to note that other modiﬁcations might have been present in
the proteins, but were not identiﬁed by the Mascot searches, for ex-
ample due to cross-linking; however, it is likely that any other mod-
iﬁcations were of relatively low abundance.
Consideration of the diﬀerences in sites of modiﬁcation is important
to understand the functional eﬀects induced. Two of the cysteine re-
sidues found modiﬁed by acrolein and HHE have been previously re-
ported to be modiﬁed by oxidation [17] or electrophilic attack by HNE
and ONE [42]. Cys326 is buried in the tetramer but accessible in the
monomeric form and a modiﬁcation at this site could prevent the re-
formation of the active tetrameric form of pyruvate kinase [17], or
destabilize the tetramer. However, in our experiments, this residue was
only observed to be modiﬁed at very high treatment concentrations,
probably reﬂecting the fact that in the tetrameric PKM1 form it is
protected. In contrast, Cys358 was susceptible to lipoxidation at lower
concentrations, although it was not the most susceptible site. This
Fig. 5. Dose- and time-dependence of aldehyde
treatment on the activity of pyruvate kinase and
viability of aldehyde-treated MCF-7 cells.
Pyruvate kinase activity is shown on the left for ac-
rolein (A), 4-hydroxyl-2(E)-hexenal (C) and mal-
ondialdehyde (E), while cell viability is shown on the
right: acrolein (B), 4-hydroxyl-2(E)-hexenal (D) and
malondialdehyde (F). Cells were treated with 2 μM,
10 μM, 20 μM, 100 μM and 200 μM of each aldehyde
for 2 h or 24 h before proteins were extracted and
10 μg of extract were used for pyruvate kinase ac-
tivity to be assessed. Cell viability assays were per-
formed with n=3 for MDA and HHE and n=4 for
ACR (Mean ± SEM; *p < 0.1 **p < 0.01,
***p < 0.001 and ****p < 0.0001). * Comparison
between treatments and control for each incubation
time. # comparison between incubation times.
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residue is located close to the substrate binding site and has previously
been reported to regulate pyruvate kinase activity by oxidation, pro-
moting optimal conditions for tumor growth and survival under oxi-
dative stress, and substitution of Cys358 by Ser358 protected PKM2
from oxidant-induced inhibition by stabilizing the tetrameric form
[15]. Acetylation of K305 had been reported to reduce pyruvate kinase
activity by lowering the aﬃnity to PEP or triggering the degradation of
the enzyme itself under nutrient-depleted conditions [51], but was only
modiﬁed at the highest MDA treatment. Cys424 in PKM2 is thought to
play a role in protein-protein interactions and allosteric regulation by F-
1,6-bP, and has been reported to be modiﬁed by electrophilic carbonyl
species [42]; this residue is not present in PKM1 but Cys423 is also
located at the subunit interface and it is conceivable that its modiﬁca-
tion can destabilize the tetrameric form. Cys423 was one of the most
sensitive residues, showing adduct formation at 10 μM acrolein and
HHE, together with Cys152. The inverse relationship between pyruvate
kinase activity and the percentage of modiﬁed peptides observed sug-
gests that the accumulation of adducts on a variety of residues con-
tributes to conformational change in the protein leading to major loss of
activity, although the possibility that increasing extent of modiﬁcation
on a single residue is responsible cannot be discounted. As losses in
activity were observed at 38 μM acrolein and HHE after 10min and
10 μM after 4 h treatments, this suggests that adducts occurring with
these treatment conditions on Cys 152, Cys358, Cys423, His 464,
Cys474 are most likely to be involved. The absence of inhibition by
short treatments with MDA despite modiﬁcation of many lysines im-
plies that none of these residues are required for activity, and may even
represent surface decoys for oxidative damage. The eventual loss of
activity above 1mM MDA probably reﬂects conformational changes
and unfolding of the protein, rather than a speciﬁc eﬀect of individual
adducts. In contrast, 2 h treatments at 100-200 μM did show slight in-
hibition, but corresponding adducts could not be detected. Never-
theless, lysine modiﬁcations were also observed following HHE and
acrolein treatments, and lysine residues have been reported to be im-
portant in regulation of pyruvate kinase: for example, inhibition
through interaction with phosphotyrosine-containing proteins occurs at
Lys433 and causes release of bound F-1,6-bP [52-54]. Possibly little
inhibition was observed in our study as F-1,6-bP was not included in the
assay. On the other hand, crosslinking of lysine residues on enzymes has
also been found to inhibit proteolysis [55].
The extractable pyruvate kinase activity in the human breast cancer
cell line MCF-7 was found to be extremely susceptible to cellular ac-
rolein treatment, with more than 80% loss of activity after 2 h of 10 μM
acrolein, in contrast to an inhibition of about 30% in vitro with the same
treatment. MDA also had a much stronger inhibitory eﬀect on cellular
pyruvate kinase, compared to the minimal eﬀect on activity in vitro and
also the lack of toxicity over the concentration range tested, whereas
the eﬀects of HHE in vitro and in vivo were similar. It is important to
note that the eﬀects of treatments in vitro and in cells cannot be directly
compared, as work in vitro was carried out with rabbit muscle pyruvate
kinase, which expresses the PKM1 isoform that is constitutively tetra-
meric with high activity, whereas the MCF-7 cells are known to contain
mainly the PKM2 isoform [56], which is allosterically regulated and
readily dissociates into dimers or monomers with lower activity.
Nevertheless, it is clear that pyruvate kinase is highly susceptible to
electrophilic inactivation despite the large number of potential protein
targets in cells. However, it is not clear from the data obtained whether
the loss of activity was due to irreversible inhibition of pyruvate kinase,
increased degradation of modiﬁed enzyme, or decreased synthesis of
active enzyme. A previous investigation of damage to cellular proteins
by HNE and ONE using click chemistry to select modiﬁed proteins
followed by shotgun proteomics identiﬁed pyruvate kinase isoforms
M1, M2 and R as susceptible proteins [57], and a recent study on the
same electrophilic compounds also reported that PKM2 in human col-
orectal carcinoma (RKO) cells was very readily modiﬁed [42], thus
supporting the hypothesis that the loss of activity relates directly to
pyruvate kinase modiﬁcation. We also observed modiﬁcations of cel-
lular pyruvate kinase by acrolein, on Cys152 and Cys358, which may
contribute to the loss of activity.
Interestingly, for both treatments the loss of activity at low treat-
ment concentrations was less severe after 24 h than 2 h. The most likely
explanation for this phenomenon is that during the longer treatment,
defence responses are activated, and cellular synthesis of the enzyme
occurs, to counteract the loss of activity. In fact, pyruvate kinase has a
relatively high turnover rate with half-life of 0.7 days [58], which could
explain the recovery of enzyme activity at 24 h compared to the 2-h
incubations at lower concentrations of aldehyde, although this turnover
rate was not measured under stress conditions. It is also well established
that covalent modiﬁcation of cellular proteins by HNE and analogous
electrophilic compounds targets them to the 20S proteasome for de-
gradation and recycling [59], although more severe treatments that
cause cross-linking via lysines as mentioned previously [55] and pro-
tein aggregation can inhibit the proteasome and ultimately lead to cell
death [60].
Changes in pyruvate kinase isoforms and activity have been re-
ported during the transformation of cells to a proliferative or tumori-
genic phenotype, and have often been linked to the switch to aerobic
glycolysis (the Warburg eﬀect) [10]. This has normally been associated
with increased glucose utilization and production of lactate. Oxidative
modiﬁcations appear to represent another way to aﬀect PKM2 activity
and coordinate the metabolic response to altered redox balance in
cancer cells. It has been suggested that inhibition of pyruvate kinase
causes a backing-up of metabolites in glycolysis as far at glucose-6-
phosphate, leading to an increased ﬂux through the pentose phosphate
pathway that facilitates antioxidant defence through increased forma-
tion of NADPH and maintenance of reduced glutathione pools [18].
This may involve inhibitory eﬀects of PEP on triose phosphate iso-
merase, based on studies in oxidatively stressed yeast [19]. There is an
apparent paradox in the fact that cancer cells manage to maintain high
lactate production despite low activity of pyruvate kinase; Harris and
Fenton have suggested that rather than inhibition per se, the PKM2
isoform has a high Km for PEP that results in a diﬀerent steady-state
ﬂux through glycolysis with high intermediate levels that support both
lactate formation and the pentose phosphate pathway [61]. However,
there is clearly evidence for elevated levels of both oxidants and anti-
oxidants in cancer [62], as well as a high susceptibility of pyruvate
kinase to oxidative and electrophilic attack, both from the data pre-
sented here and previous studies [15,17,19,42]. In the case of inhibition
by electrophilic species that cause covalent adduct formation, it seems
likely that increased ﬂux through the pentose phosphate pathway and
altered metabolic state also allows increased protein synthesis to
maintain key enzyme activities.
In summary, this study has provided novel data on the susceptibility
of the key glycolytic enzyme pyruvate kinase to modiﬁcation by 3 al-
dehydes with diﬀerent chemical reactivities: acrolein (an alkenal), HHE
(a hydroxyalkenal), and MDA (a dicarbonyl), and has shown that they
cause diﬀerential inhibition of activity both in vitro and in a breast
cancer cell line. Pyruvate kinase in MCF-7 cells was extremely suscep-
tible to inhibition and modiﬁcation by acrolein, which is a carcinogen
present in tobacco smoke as well as a product of lipid peroxidation, thus
suggesting an additional mechanism by which this compound may
contribute to tumorigenesis.
Funding/Acknowledgments
This project has received funding from the European Union's
Horizon 2020 research and innovation programme under the Marie
Sklowdowska-Curie grant agreement number 675132 www.masstrplan.
org. The data are available online at Aston Research Data Explorer
https://doi.org/10.17036/researchdata.aston.ac.uk.00000415.
B.C. Sousa, et al. Free Radical Biology and Medicine xxx (xxxx) xxx–xxx
9
Appendix A. Supplementary data


















PROS partially reduced oxygen species
PUFA polyunsaturated fatty acid
QUAD quadrupole
Rt Retention time
TOF time of ﬂight
References
[1] O. Warburg, On the origin of cancer cells, Science 123 (1956) 309–314.
[2] M.V. Gwangwa, A.M. Joubert, M.H. Visagie, Crosstalk between the Warburg eﬀect,
redox regulation and autophagy induction in tumourigenesis, Cell. Mol. Biol. Lett.
23 (2018) 20.
[3] S.W. Kang, S. Lee, E.K. Lee, ROS and energy metabolism in cancer cells: alliance for
fast growth, Arch Pharm. Res. (Seoul) 38 (2015) 338–345.
[4] V. Sosa, T. Moline, R. Somoza, R. Paciucci, H. Kondoh, L.L. ME, Oxidative stress and
cancer: an overview, Ageing Res. Rev. 12 (2013) 376–390.
[5] E. Mullarky, L.C. Cantley, Diverting glycolysis to combat oxidative stress, in:
K. Nakao, N. Minato, S. Uemoto (Eds.), Innovative Medicine: Basic Research and
Development. Tokyo, 2015, pp. 3–23.
[6] P. Eaton, N. Wright, D.J. Hearse, M.J. Shattock, Glyceraldehyde phosphate dehy-
drogenase oxidation during cardiac ischemia and reperfusion, J. Mol. Cell. Cardiol.
34 (2002) 1549–1560.
[7] T. Ishii, O. Sunami, H. Nakajima, H. Nishio, T. Takeuchi, F. Hata, Critical role of
sulfenic acid formation of thiols in the inactivation of glyceraldehyde-3-phosphate
dehydrogenase by nitric oxide, Biochem. Pharmacol. 58 (1999) 133–143.
[8] J.M. Souza, R. Radi, Glyceraldehyde-3-phosphate dehydrogenase inactivation by
peroxynitrite, Arch. Biochem. Biophys. 360 (1998) 187–194.
[9] M. Yi, Y. Ban, Y. Tan, W. Xiong, G. Li, B. Xiang, 6-Phosphofructo-2-kinase/fructose-
2,6-biphosphatase 3 and 4: a pair of valves for ﬁne-tuning of glucose metabolism in
human cancer, Mol Metab 20 (2019) 1–13.
[10] W. Luo, G.L. Semenza, Emerging roles of PKM2 in cell metabolism and cancer
progression, Trends Endocrinol. Metabol. 23 (2012) 560–566.
[11] H.R. Christofk, M.G. Vander Heiden, M.H. Harris, A. Ramanathan, R.E. Gerszten,
R. Wei, M.D. Fleming, S.L. Schreiber, L.C. Cantley, The M2 splice isoform of pyr-
uvate kinase is important for cancer metabolism and tumour growth, Nature 452
(2008) 230–233.
[12] K. Ashizawa, P. McPhie, K.H. Lin, S.Y. Cheng, An in vitro novel mechanism of
regulating the activity of pyruvate kinase M2 by thyroid hormone and fructose 1, 6-
bisphosphate, Biochemistry 30 (1991) 7105–7111.
[13] J.D. Dombrauckas, B.D. Santarsiero, A.D. Mesecar, Structural basis for tumor pyr-
uvate kinase M2 allosteric regulation and catalysis, Biochemistry 44 (2005)
9417–9429.
[14] M.S. Jurica, A. Mesecar, P.J. Heath, W. Shi, T. Nowak, B.L. Stoddard, The allosteric
regulation of pyruvate kinase by fructose-1,6-bisphosphate, Structure 6 (1998)
195–210.
[15] D. Anastasiou, G. Poulogiannis, J.M. Asara, M.B. Boxer, J.K. Jiang, M. Shen,
G. Bellinger, A.T. Sasaki, J.W. Locasale, D.S. Auld, C.J. Thomas, M.G. Vander
Heiden, L.C. Cantley, Inhibition of pyruvate kinase M2 by reactive oxygen species
contributes to cellular antioxidant responses, Science 334 (2011) 1278–1283.
[16] B. McDonagh, S. Ogueta, G. Lasarte, C.A. Padilla, J.A. Barcena, Shotgun redox
proteomics identiﬁes speciﬁcally modiﬁed cysteines in key metabolic enzymes
under oxidative stress in Saccharomyces cerevisiae, J. Proteom. 72 (2009) 677–689.
[17] A.R. Mitchell, M. Yuan, H.P. Morgan, I.W. McNae, E.A. Blackburn, T. Le Bihan,
R.A. Homem, M. Yu, G.J. Loake, P.A. Michels, M.A. Wear, M.D. Walkinshaw, Redox
regulation of pyruvate kinase M2 by cysteine oxidation and S-nitrosation, Biochem.
J. 475 (2018) 3275–3291.
[18] S.Y. Lunt, V. Muralidhar, A.M. Hosios, W.J. Israelsen, D.Y. Gui, L. Newhouse,
M. Ogrodzinski, V. Hecht, K. Xu, P.N. Acevedo, D.P. Hollern, G. Bellinger,
T.L. Dayton, S. Christen, I. Elia, A.T. Dinh, G. Stephanopoulos, S.R. Manalis,
M.B. Yaﬀe, E.R. Andrechek, S.M. Fendt, M.G. Vander Heiden, Pyruvate kinase
isoform expression alters nucleotide synthesis to impact cell proliferation, Mol. Cell
57 (2015) 95–107.
[19] N.M. Gruning, M. Rinnerthaler, K. Bluemlein, M. Mulleder, M.M. Wamelink,
H. Lehrach, C. Jakobs, M. Breitenbach, M. Ralser, Pyruvate kinase triggers a me-
tabolic feedback loop that controls redox metabolism in respiring cells, Cell
Metabol. 14 (2011) 415–427.
[20] E. Eigenbrodt, M. Reinacher, U. Scheefers-Borchel, H. Scheefers, R. Friis, Double
role for pyruvate kinase type M2 in the expansion of phosphometabolite pools
found in tumor cells, Crit. Rev. Oncog. 3 (1992) 91–115.
[21] B.C. Sousa, A.R. Pitt, C.M. Spickett, Chemistry and analysis of HNE and other
prominent carbonyl-containing lipid oxidation compounds, Free Radical Biol. Med.
111 (2017) 294–308.
[22] A. Reis, C.M. Spickett, Chemistry of phospholipid oxidation, Biochim. Biophys. Acta
1818 (2012) 2374–2387.
[23] R.M. Domingues, P. Domingues, T. Melo, D. Perez-Sala, A. Reis, C.M. Spickett,
Lipoxidation adducts with peptides and proteins: deleterious modiﬁcations or sig-
naling mechanisms? J. Proteom. 92 (2013) 110–131.
[24] S. Pizzimenti, E. Ciamporcero, M. Daga, P. Pettazzoni, A. Arcaro, G. Cetrangolo,
R. Minelli, C. Dianzani, A. Lepore, F. Gentile, G. Barrera, Interaction of aldehydes
derived from lipid peroxidation and membrane proteins, Front. Physiol. 4 (2013)
242.
[25] G. Barrera, S. Pizzimenti, E.S. Ciamporcero, M. Daga, C. Ullio, A. Arcaro,
G.P. Cetrangolo, C. Ferretti, C. Dianzani, A. Lepore, F. Gentile, Role of 4-hydro-
xynonenal-protein adducts in human diseases, Antioxidants Redox Signal. 22
(2015) 1681–1702.
[26] F.J. Van Kuijk, L.L. Holte, E.A. Dratz, 4-Hydroxyhexenal: a lipid peroxidation
product derived from oxidized docosahexaenoic acid, Biochim. Biophys. Acta 1043
(1990) 116–118.
[27] A. Ayala, M.F. Munoz, S. Arguelles, Lipid peroxidation: production, metabolism,
and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal, Oxid.
Med. Cell. Longev. 2014 (2014) 360438.
[28] M. Khoubnasabjafari, K. Ansarin, A. Jouyban, Reliability of malondialdehyde as a
biomarker of oxidative stress in psychological disorders, Bioimpacts : BI 5 (2015)
123–127.
[29] H.J. Forman, O. Augusto, R. Brigelius-Flohe, P.A. Dennery, B. Kalyanaraman,
H. Ischiropoulos, G.E. Mann, R. Radi, L.J. Roberts 2nd, J. Vina, K.J. Davies, Even
free radicals should follow some rules: a guide to free radical research terminology
and methodology, Free Radical Biol. Med. 78 (2015) 233–235.
[30] D. Del Rio, A.J. Stewart, N. Pellegrini, A review of recent studies on mal-
ondialdehyde as toxic molecule and biological marker of oxidative stress, Nutr.
Metabol. Cardiovasc. Dis. : Nutr. Metabol. Cardiovasc. Dis. 15 (2005) 316–328.
[31] D. Aizenbud, I. Aizenbud, A.Z. Reznick, K. Avezov, Acrolein-an alpha,beta-un-
saturated aldehyde: a review of oral cavity exposure and oral pathology eﬀects,
Rambam Maimonides Med. J. 7 (2016).
[32] K. Uchida, M. Kanematsu, Y. Morimitsu, T. Osawa, N. Noguchi, E. Niki, Acrolein is a
product of lipid peroxidation reaction. Formation of free acrolein and its conjugate
with lysine residues in oxidized low density lipoproteins, J. Biol. Chem. 273 (1998)
16058–16066.
[33] J.P. Kehrer, S.S. Biswal, The molecular eﬀects of acrolein, Toxicol. Sci. : Oﬀ. J. Soc.
Toxicol. 57 (2000) 6–15.
[34] J.F. Stevens, C.S. Maier, Acrolein: sources, metabolism, and biomolecular interac-
tions relevant to human health and disease, Mol. Nutr. Food Res. 52 (2008) 7–25.
[35] H. Zhong, H. Yin, Role of lipid peroxidation derived 4-hydroxynonenal (4-HNE) in
cancer: focusing on mitochondria, Redox Biol 4 (2015) 193–199.
[36] G. Barrera, Oxidative stress and lipid peroxidation products in cancer progression
and therapy, ISRN Oncol 2012 (2012) 137289.
[37] K. Uchida, E.R. Stadtman, Covalent attachment of 4-hydroxynonenal to glycer-
aldehyde-3-phosphate dehydrogenase. A possible involvement of intra- and inter-
molecular cross-linking reaction, J. Biol. Chem. 268 (1993) 6388–6393.
[38] M. Nakamura, H. Tomitori, T. Suzuki, A. Sakamoto, Y. Terui, R. Saiki, N. Dohmae,
K. Igarashi, K. Kashiwagi, Inactivation of GAPDH as one mechanism of acrolein
toxicity, Biochem. Biophys. Res. Commun. 430 (2013) 1265–1271.
[39] K. Igarashi, T. Uemura, K. Kashiwagi, Acrolein toxicity at advanced age: present and
future, Amino Acids 50 (2018) 217–228.
[40] J. Gerszon, A. Rodacka, Oxidatively modiﬁed glyceraldehyde-3-phosphate dehy-
drogenase in neurodegenerative processes and the role of low molecular weight
compounds in counteracting its aggregation and nuclear translocation, Ageing Res.
Rev. 48 (2018) 21–31.
[41] C.J. Martyniuk, B. Fang, J.M. Koomen, T. Gavin, L. Zhang, D.S. Barber,
R.M. Lopachin, Molecular mechanism of glyceraldehyde-3-phosphate dehy-
drogenase inactivation by alpha,beta-unsaturated carbonyl derivatives, Chem. Res.
Toxicol. 24 (2011) 2302–2311.
[42] J.M. Camarillo, J.C. Ullery, K.L. Rose, L.J. Marnett, Electrophilic modiﬁcation of
PKM2 by 4-hydroxynonenal and 4-oxononenal results in protein cross-linking and
kinase inhibition, Chem. Res. Toxicol. 30 (2017) 635–641.
[43] L. Soulere, Y. Queneau, A. Doutheau, An expeditious synthesis of 4-hydroxy-2E-
nonenal (4-HNE), its dimethyl acetal and of related compounds, Chem. Phys. Lipids
150 (2007) 239–243.
[44] S. Bouzbouz, E. de Lemos, J. Cossy, J. Saez, X. Franck, B. Figadere, Natural (5′-
oxoheptene-1′E,3′E-dienyl)-5,6-dihydro-2H- Pyran-2-One: Total Synthesis and
B.C. Sousa, et al. Free Radical Biology and Medicine xxx (xxxx) xxx–xxx
10
Revision of its Absolute Conﬁguration, (2004).
[45] I. Verrastro, K. Tveen-Jensen, R. Woscholski, C.M. Spickett, A.R. Pitt, Reversible
oxidation of phosphatase and tensin homolog (PTEN) alters its interactions with
signaling and regulatory proteins, Free Radical Biol. Med. 90 (2016) 24–34.
[46] C.B. Afonso, B.C. Sousa, A.R. Pitt, C.M. Spickett, A mass spectrometry approach for
the identiﬁcation and localization of small aldehyde modiﬁcations of proteins,
Arch. Biochem. Biophys. 646 (2018) 38–45.
[47] M.H. El-Maghrabey, N. Kishikawa, K. Ohyama, N. Kuroda, Analytical method for
lipoperoxidation relevant reactive aldehydes in human sera by high-performance
liquid chromatography-ﬂuorescence detection, Anal. Biochem. 464 (2014) 36–42.
[48] K. Sakata, K. Kashiwagi, S. Sharmin, S. Ueda, Y. Irie, N. Murotani, K. Igarashi,
Increase in putrescine, amine oxidase, and acrolein in plasma of renal failure pa-
tients, Biochem. Biophys. Res. Commun. 305 (2003) 143–149.
[49] W.J. Israelsen, M.G. Vander Heiden, Pyruvate kinase: function, regulation and role
in cancer, Semin. Cell Dev. Biol. 43 (2015) 43–51.
[50] W.J. Israelsen, T.L. Dayton, S.M. Davidson, B.P. Fiske, A.M. Hosios, G. Bellinger,
J. Li, Y. Yu, M. Sasaki, J.W. Horner, L.N. Burga, J. Xie, M.J. Jurczak, R.A. DePinho,
C.B. Clish, T. Jacks, R.G. Kibbey, G.M. Wulf, D. Di Vizio, G.B. Mills, L.C. Cantley,
M.G. Vander Heiden, PKM2 isoform-speciﬁc deletion reveals a diﬀerential re-
quirement for pyruvate kinase in tumor cells, Cell 155 (2013) 397–409.
[51] L. Lv, D. Li, D. Zhao, R. Lin, Y. Chu, H. Zhang, Z. Zha, Y. Liu, Z. Li, Y. Xu, G. Wang,
Y. Huang, Y. Xiong, K.L. Guan, Q.Y. Lei, Acetylation targets the M2 isoform of
pyruvate kinase for degradation through chaperone-mediated autophagy and pro-
motes tumor growth, Mol. Cell 42 (2011) 719–730.
[52] H.R. Christofk, M.G. Vander Heiden, N. Wu, J.M. Asara, L.C. Cantley, Pyruvate
kinase M2 is a phosphotyrosine-binding protein, Nature 452 (2008) 181–186.
[53] T. Hitosugi, S. Kang, M.G. Vander Heiden, T.W. Chung, S. Elf, K. Lythgoe, S. Dong,
S. Lonial, X. Wang, G.Z. Chen, J. Xie, T.L. Gu, R.D. Polakiewicz, J.L. Roesel,
T.J. Boggon, F.R. Khuri, D.G. Gilliland, L.C. Cantley, J. Kaufman, J. Chen, Tyrosine
phosphorylation inhibits PKM2 to promote the Warburg eﬀect and tumor growth,
Sci. Signal. 2 (2009) ra73.
[54] B. Varghese, G. Swaminathan, A. Plotnikov, C. Tzimas, N. Yang, H. Rui, S.Y. Fuchs,
Prolactin inhibits activity of pyruvate kinase M2 to stimulate cell proliferation, Mol.
Endocrinol. 24 (2010) 2356–2365.
[55] B. Friguet, L.I. Szweda, Inhibition of the multicatalytic proteinase (proteasome) by
4-hydroxy-2-nonenal cross-linked protein, FEBS Lett. 405 (1997) 21–25.
[56] K. Taniguchi, Y. Ito, N. Sugito, M. Kumazaki, H. Shinohara, N. Yamada,
Y. Nakagawa, T. Sugiyama, M. Futamura, Y. Otsuki, K. Yoshida, K. Uchiyama,
Y. Akao, Organ-speciﬁc PTB1-associated microRNAs determine expression of pyr-
uvate kinase isoforms, Sci. Rep. 5 (2015) 8647.
[57] S.G. Codreanu, J.C. Ullery, J. Zhu, K.A. Tallman, W.N. Beavers, N.A. Porter,
L.J. Marnett, B. Zhang, D.C. Liebler, Alkylation damage by lipid electrophiles tar-
gets functional protein systems, Mol. Cell. Proteom. 13 (2014) 849–859.
[58] D. Illg, D. Pette, Turnover rates of hexokinase I, phosphofructokinase, pyruvate
kinase and creatine kinase in slow-twitch soleus muscle and heart of the rabbit, Eur.
J. Biochem. 97 (1979) 267–273.
[59] J.P. Castro, T. Jung, T. Grune, W. Siems, 4-Hydroxynonenal (HNE) modiﬁed pro-
teins in metabolic diseases, Free Radical Biol. Med. 111 (2017) 309–315.
[60] A. Hohn, T. Jung, T. Grune, Pathophysiological importance of aggregated damaged
proteins, Free Radical Biol. Med. 71 (2014) 70–89.
[61] R.A. Harris, A.W. Fenton, A critical review of the role of M2PYK in the Warburg
eﬀect, Biochim. Biophys. Acta Rev. Canc. 1871 (2019) 225–239.
[62] A. Glasauer, N.S. Chandel, Targeting antioxidants for cancer therapy, Biochem.
Pharmacol. 92 (2014) 90–101.
B.C. Sousa, et al. Free Radical Biology and Medicine xxx (xxxx) xxx–xxx
11
